1-5 of 5
Spencer Henick Bachow
Close
Sort by
Journal Articles

Time-Limited Bendamustine, Rituximab, and Venetoclax (BR-VR) in Untreated Chronic Lymphocytic Leukemia (CLL): High Rates of Undetectable Minimal Residual Disease Remissions

Andrew H. Lipsky, Brian T. Hill, Allison Winter, Spencer Henick Bachow, Aaron D. Viny, Todd L. Rosenblat, Joseph Jurcic, Nicole Lamanna
Journal: Blood
Blood (2023) 142 (Supplement 1): 3274.
https://doi.org/10.1182/blood-2023-189718
Published: 2023
Journal Articles

Optimal Sequencing of Ibrutinib, Idelalisib, and Venetoclax in CLL: Results from a Large Multi-Center Study of 683 US-Patients

Anthony R. Mato, MD MSCE, Brian T. Hill, MD PhD, Nicole Lamanna, MD, Paul Barr, MD, Chaitra S. Ujjani, MD, Danielle M. Brander, MD, Christina Howlett, PharmD, BCOP, Alan P Skarbnik, MD, Bruce Cheson, MD, Clive S Zent, MD, Jeffrey J Pu, MD PhD, Pavel Kiselev, PhD, Spencer Henick Bachow, MD, Allison M Winter, MD, Allan-Louie Cruz, MD, David F. Claxton, MD, Catherine Daniel, MD, Krista Isaack, DO, Kaitlin H Kennard, BSN, Colleen Timlin, PharmD, Molly Fanning, BS, Melissa Yacur, MD, Jakub Svoboda, MD, Stephen J. Schuster, MD, Chadi Nabhan, MD MBA, FACP
Journal: Blood
Blood (2016) 128 (22): 4400.
https://doi.org/10.1182/blood.V128.22.4400.4400
Published: 2016
Journal Articles

Toxicities and Outcomes of Ibrutinib-Treated Patients in the United States: Large Retrospective Analysis of 621 Real World Patients

Anthony R. Mato, MDMSCE, Nicole Lamanna, MD, Chaitra S. Ujjani, MD, Danielle M. Brander, MD, Brian T. Hill, MD PhD, Christina Howlett, PharmD, BCOP, Alan P Skarbnik, MD, Bruce Cheson, MD, Clive S Zent, MD, Jeffrey J Pu, MD PhD, Pavel Kiselev, PhD, Spencer Henick Bachow, MD, Allison M Winter, MD, Allan-Louie Cruz, MD, David F. Claxton, MD, Catherine Daniel, MD, Krista Isaack, DO, Kaitlin H Kennard, BSN, Colleen Timlin, PharmD, Melissa Yacur, MD, Molly Fanning, BS, Lauren E. Strelec, BA, Daniel J. Landsburg, MD, Sunita Dwivedy Nasta, MD, Stephen J. Schuster, MD, David L Porter, MD, Chadi Nabhan, MD MBA, FACP, Paul Barr, MD
Journal: Blood
Blood (2016) 128 (22): 3222.
https://doi.org/10.1182/blood.V128.22.3222.3222
Published: 2016
Journal Articles

Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience

Clinical Trials & Observations
Anthony R. Mato, Chadi Nabhan, Paul M. Barr, Chaitra S. Ujjani, Brian T. Hill, Nicole Lamanna, Alan P. Skarbnik, Christina Howlett, Jeffrey J. Pu, Alison R. Sehgal, Lauren E. Strelec, Alexandra Vandegrift, Danielle M. Fitzpatrick, Clive S. Zent, Tatyana Feldman, Andre Goy, David F. Claxton, Spencer Henick Bachow, Gurbakhash Kaur, Jakub Svoboda, Sunita Dwivedy Nasta, David Porter, Daniel J. Landsburg, Stephen J. Schuster, Bruce D. Cheson, Pavel Kiselev, Andrew M. Evens
Journal: Blood
Blood (2016) 128 (18): 2199–2205.
https://doi.org/10.1182/blood-2016-05-716977
Published: 2016
Includes: Supplemental data
Journal Articles

Favorable Outcomes in CLL Pts with Alternate Kinase Inhibitors Following Ibrutinib or Idelalisib Discontinuation: Results from a Large Multi-Center Study

Anthony Mato, MD, Chadi Nabhan, MD, Paul M. Barr, MD, Chaitra S. Ujjani, MD, Brian T. Hill, MD PhD, Nicole Lamanna, MD, Alan P Skarbnik, MD, Christina Howlett, PharmD, BCOP, Jeffrey J Pu, MD PhD, Alison R. Sehgal, MD, Lauren E. Strelec, BA, Alexandra Vandegrift, BA, Allison Rago, BSN, Clive S Zent, MD, Tatyana Feldman, MD, Andre Goy, MD, David F. Claxton, MD, Spencer Henick Bachow, MD, Gurbakhash Kaur, MD BS, MA, Jakub Svoboda, MD, Sunita Dwivedy Nasta, MD, David Porter, MD, Daniel J. Landsburg, MD, Stephen J. Schuster, MD, Bruce D. Cheson, MD, Andrew M. Evens, DO, MSc
Journal: Blood
Blood (2015) 126 (23): 719.
https://doi.org/10.1182/blood.V126.23.719.719
Published: 2015